Brian Leyland-Jones, MBBS, PhD

Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the results of the SWOG S0500 trial, which looked at circulating tumor cell (CTC) levels in patients with metastatic breast cancer. Results of the trial were presented at the 2013 San Antonio Breast Cancer Symposium.

The trial set out to determine whether CTC levels could be used to guide the frontline treatment of metastatic breast cancer

It was hypothesized that those patients who maintained a high level of CTCs would do badly

Patients with low CTC levels before and after chemotherapy did best

Patients with elevated CTC levels before chemotherapy but lower levels after chemotherapy did moderately well

Patients with elevated CTC levels before and after chemotherapy did poorly

This trial demonstrated how dramatic the differences were in prognosis amongst the three groups

Articles

Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the results of the SWOG S0500 trial, which looked at circulating tumor cell (CTC) levels in patients with metastatic breast cancer.

Results of the SWOG S0500 Trial

Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, gives an overview of a trial that looks at all aspects of sequencing in breast cancer.

A 25-patient trial will analyze all the aspects of sequencing including whole genome sequencing and exome sequencing

The data from the trial will help guide therapy

Videos

Brian Leyland-Jones, MBBS, PhD, gives an overview of a trial that looks at all aspects of sequencing in breast cancer.

Sequencing in Breast Cancer

Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the use of erythropoiesis stimulating agents (ESAs) in patients with breast cancer.

There has been a lot of controversy in this space. At the 2013 Breast Cancer Symposium, Leyland-Jones presented the latest meta-analysis, which looked at 9 current studies in breast cancer randomizing ESAs versus no ESAs.

The meta-analysis looked at 5 endpoints and found that mortality increased 20% when using ESAs. In studies with target hemoglobin levels at or less than 12 grams per deciliter (g/dL), the hazard ratio was reduced to 1.03. Leyland-Jones says that when using ESAs, the target hemoglobin levels must be reduced to 12 g/dL to reduce the mortality rate.

There has been a lot of controversy over the use of ESAs in breast cancer

The latest meta-analysis looked at 9 current studies which randomized ESAs vs no ESAs

Brian Leyland-Jones, MBBS, PhD | Authors

Articles

Results of the SWOG S0500 Trial

Sequencing in Breast Cancer

The Use of ESAs in Patients With Breast Cancer